Книги: "Rheumatoid arthritis Immunological aspects"

1

Radboud J. E. M. Dolhain. T cells in the inflamed joints of patients with rheumatoid arthritis. [Leiden: University of Leiden, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

David, Isenberg, and Rademacher T. W, eds. Abnormalities of IgG glycosylation and immunological disorders. Chichester: Wiley, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

S, Panayi Gabriel, ed. Immunology of the connective tissue diseases. Dordrecht: Kluwer Academic Publishers, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

M, Cutolo, and New York Academy of Sciences., eds. Basic and clinical aspects of neuroendocrine immunology in rheumatic diseases. Boston, Mass: Blackwell Pub. on behalf of the New York Academy of Sciences, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

H, Phillips Robert. Coping with rheumatoid arthritis. Garden City Park, N.Y: Avery Pub. Group, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Pritchard, Mary L. Psychological aspects of rheumatoid arthritis. New York: Springer-Verlag, 1989.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Pritchard, Mary L. Psychological Aspects of Rheumatoid Arthritis. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4613-9666-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Leitch, Michael. Living with arthritis: People with arthritis talk about coping from day to day. Bath: Chivers, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

C, Singleton Mary, and Branch Eleanor F, eds. Physical therapy and the arthritis patient: Clinical aspects and approaches to management. New York: Haworth Press, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Ronday, H. K. Aspects of proteolytic joint destruction in rheumatoid arthritis. Leiden: University of Leiden, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Rona, Zoltan P. Rheumatoid arthritis: Decrease or reverse symptoms-naturally. Vancouver: Alive Books, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Rona, Zoltan P. Rheumatoid arthritis: Decrease or reverse symptoms-- naturally. Summertown, Tenn: Alive books, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Mäkeläinen, Paula. Rheumatoid arthritis patient education and self-efficacy. Kuopio: Kuopion Yliopisto, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Mäkeläinen, Paula. Rheumatoid arthritis patient education and self-efficacy. Kuopio: Kuopion Yliopisto, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Taal, Erik. Self-efficacy, self-management, and patient education in rheumatoid arthritis. Delft, the Netherlands: Eburon, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Nordenskiöld, Ulla. Daily activities in women with rheumatoid arthritis: Aspects of patient education, assistive devices and methods for disability and impairment assessment. Oslo: Scandinavian University Press, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Zierhut, Manfred. Immunology of the joint and the eye. Boston: Butterworth-Heinemann, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Poehlmann, Katherine M. Rheumatoid arthritis: The infection connection : targeting and treating the cause of chronic illness. Rolling Hills Estates, CA: Satori Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Nelsen, Laura. Free from pain of rheumatoid arthritis: Without drugs, exercise, or diet : new safe, simple, do-it-yourself methods anyone can use. Phoenix, Ariz: Sundance Pub. Co., 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Hayes, Diana L. Trouble don't last always: Soul prayers. Collegeville, Minn: Liturgical Press, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

1953-, López-Larrea Carlos, ed. HLA-B27 in the development of spondyloarthropathies. New York: Springer, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

1954-, Kresina Thomas F., ed. Monoclonal antibodies, cytokines, and arthritis: Mediators of inflammation and therapy. New York: M. Dekker, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lahita, Robert, J. W. J. Bijlsma, Alfonse Masi, and Rainer Straub. Basic and Clinical Aspects of Neuroendocrine Immunology in Rheumatic Diseases (Annals of the New York Academy of Sciences). Blackwell Publishing Limited, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Pritchard, Mary L. Psychological Aspects of Rheumatoid Arthritis. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Shirazi, Aida. Nutrient intake of women with rheumatoid arthritis before and after receiving arthritis medication. 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Scott, David L., James Galloway, Andrew Cope, Arthur Pratt, and Vibeke Strand, eds. Oxford Textbook of Rheumatoid Arthritis. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.001.0001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This new textbook provides a comprehensive overview of the scientific and clinical aspects of rheumatoid arthritis (RA). Split into eight sections—history, diagnosis, and epidemiology; pathogenesis; clinical presentation; disease assessment; impact on life; non-drug treatments; drug treatments; and management and outcomes—it collects the contemporary ideas about RA and explains the revolutionary changes that have taken place over the past two decades, and indicates areas of future research. Witten by leading clinicians and scientists in the field, each chapter gives a detailed background, key recent advances, areas of doubt, and future directions of research.

27

1955-, Miossec Pierre, Berg, Wim B. van den, 1950-, and Firestein Gary S, eds. T cells in arthritis. Basel: Birkhauser Verlag, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Pilkington, Clarissa. Juvenile idiopathic arthritis: medical aspects. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199550647.003.013002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

♦ Juvenile idiopathic arthritis is defined as an arthritis persisting for at least 6 weeks♦ The cause may relate to the immune system response to a stimulus with a synovial or systemic manifestation♦ Classification depends on the clinical picture and the immunological markers♦ Joint sepsis is often a differential diagnosis♦ Most cases respond to simple measures, a few need a structured medical management plan. Surgery is indicated in 10% of cases. All require physiotherapy♦ Complications may occur secondary to the disease or its treatment.

29

Strahl, Carolyn Jane. The role of pain anxiety, coping strategies, and self-efficacy in rheumatoid arthritis patient funtioning. 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Scarpa, Raffaele, Francesco Caso, Luisa Costa, Rosario Peluso, Nicola Matteo Dario Di Minno, and Antonio Del Puente. Peripheral arthritis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Clinical presentation of peripheral arthritis in patients with psoriatic arthritis (PsA), has been described by Moll and Wright who classified it into four subsets: symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis and arthritis mutilans. In the symmetrical polyarthritis subset, the distribution of articular involvement is similar to rheumatoid arthritis and this has for many years justified the inappropriate use of the terminology ‘rheumatoid-like form’, at present completely abandoned. Oligoarthritis is characterized by asymmetrical involvement of few joints (less than four), which include scattered DIP or proximal interphalangeal (PIP) joints and/or metatarsophalangeal joints. DIP arthritis may occur with symmetrical or asymmetrical features, and it is often in strict association with onycopathy. The arthritis mutilans pattern is characterized by osteolysis of phalanx and metacarpals and it is very rare, occurring in less than 1% of patients with established form of arthritis. In 15-20% of the cases the arthritis may precede the onset of the psoriatic skin rash. Consequently, psoriatic arthritis ‘sine psoriasis’ should not be considered a rare clinical finding. In this subset articular involvement is clinically expressed, while cutaneous is apparently absent. Laboratory tests and imaging are relevant for differential diagnosis which in some presentations may represent a diagnostic challenge. The outcome of peripheral patterns of PsA patients is related not only to the spectrum of peripheral phenotypes, but also to early diagnosis, and metabolic aspects, which may affect excess in morbidity and mortality.

31

Avery, Andrea. Sonata: A Memoir of Pain and the Piano. Norton & Company, Incorporated, W. W., 2018.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Avery, Andrea. Sonata: A memoir of pain and the piano. 2017.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Avery, Andrea. Sonata. Pegasus Books, 2017.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Witte, Maria-Brigitta. Koharenzgefuhl Und Krankheits-verarbeitung Bei Patientinnen Und Patienten Mit Chronischer Polyarthritis (Europaische Hochschulschriften: Reihe). Peter Lang Publishing, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

J, Carlson-Newberry Sydne, Southern California Evidence-Based Practice Center/RAND., and United States. Agency for Healthcare Research and Quality., eds. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2004.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Lopez-Larrea, Carlos. Hla-B27 in the Development of Spondyloarthropathies. R G Landes Co, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Malaviya, Anand, and Ashok Kumar. Axial spondyloarthritis in India. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198734444.003.0030.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Spondyloarthritis (SpA) is among the commonest rheumatological conditions in India, second only to rheumatoid arthritis (RA). This is consistent with the fact that the prevalence of SpA is linked to the prevalence of HLA-B27 in that population. Its prevalence in different regions of the country has been reported to be approximately 6%. That would put India prominently on the SpA map of the world, reflected in the large number of publications from the late 1970s onwards, dispelling any earlier misconceptions that it is largely a ‘white man’s disease’. This chapter summarizes the various aspects of SpA as reported from India.

38

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0030.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, 'first-in-human' to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

39

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

40

Strand, Vibeke, Jeremy Sokolove, and Alvina D. Chu. Design of clinical trials in rheumatology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199642489.003.0030_update_002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Development of new therapies for rheumatic diseases requires a series of randomized controlled trials (RCTs) progressing from phase 1, ’first-in-human’ to generate initial safety, pharmacokinetic (PK) and pharmacodynamic (PD) data; to phase 2, proof of concept for efficacy with safety and PK/PD data; and phase 3, designed to demonstrate definitive efficacy and safety to support regulatory approval. Important aspects of RCT designs include sample size estimations, treatment allocation, rescue, blinding, and statistical analyses of prespecified endpoints to preserve trial integrity. Over the past 15 years, significant progress has been made in the design of RCTs in rheumatoid arthritis (RA). Similarly, development and validation of composite outcome measures in psoriatic arthritis, ankylosing spondylitis, gout, and osteoarthritis have furthered trial design and treatment approvals. RCTs in systemic lupus erythematosus and other multisystem, heterogeneous diseases pose more challenges. Trial design will continue to evolve as promising therapies are introduced into the clinic.

41

Price, Elizabeth J., and Anwar R. Tappuni, eds. Oxford Textbook of Sjögren's Syndrome. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198806684.001.0001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The Oxford Textbook of Sjögren’s Syndrome is an authoritative textbook, rich with valuable illustrations and figures, providing a practical guide to diagnosing and managing all aspects of this condition. Sjögren’s syndrome is a chronic, immune-mediated condition typically presenting in women in their fifth or sixth decade. With increased awareness and improvement in diagnostic tests, younger women and occasionally men are now being diagnosed with this condition. Frequently, Sjögren’s syndrome occurs in association with other autoimmune diseases, usually rheumatoid arthritis, systemic lupus erythematosus, or scleroderma. The hallmark of this condition is dryness of the eyes and mouth, but many patients have systemic effects that can be debilitating, including fatigue, peripheral neuropathy, and lung damage. It has potentially serious long-term complications, including a higher risk of developing lymphoma and foetal congenital heart block. Diagnosis of the condition can be challenging as the presenting symptoms are variable. Management of the condition can be complex as the course of the disease is unpredictable and the available therapy is mainly symptomatic, with no known cure as yet. Experts in the condition from around the world have contributed to this book to provide the most up-to-date information on pathophysiology, classification criteria, diagnostic tests, systemic manifestations of the disease, and emerging therapeutic options. The publication of this book coincides with a period of increased interest in Sjögren’s within the scientific, medical, and pharmacological worlds.

Книги з теми "Rheumatoid arthritis Immunological aspects"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями